Market research
AVCN.TO Avicanna Inc
TO CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 17M
- P/E ratio
- Not available
- Analyst target
- 0.7
- Beta
- Not available
Profile
Company facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA05368K1003
- Market cap
- 17M
- P/E ratio
- Not available
- Analyst target
- 0.7
- Beta
- Not available
About
About Avicanna Inc
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for medical and pharmaceutical markets in Canada and internationally. It provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific cannabinoid-based candidates to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders, as well as Trunerox, an indication-specific drug treatment for seizure associated with Lennox-Gastaut Syndrome and Dravet Syndrome. The company also offers active pharmaceutical ingredients comprising various cannabidiol, tetrahydrocannabinol, and cannabigerol for use in the development and production of food, cosmetics, medical, and pharmaceutical products under the Aureus Santa Marta brand. In addition, it operates MyMedi.ca, a medical cannabis care platform that offers a diverse portfolio of products and bilingual pharmacist-led patient support programs, specialty services to veterans, as well as provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens; and collaborates with public and private payers for adjudication and reimbursement. The company has a research and collaboration agreement with a multinational European based pharmaceutical company to assess its proprietary SEDDS technology in combination with Collaborator's various drug delivery and pharmaceutical formats. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AVCN.TO discussion.
5 years, 5 months ago
Avicanna Inc is currently in a long term downtrend where the price is trading 0.1% below its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.8.
Avicanna Inc's total revenue rose by 17742.5% to $882K since the same quarter in the previous year.
Its net income has dropped by 10.1% to $-7M since the same quarter in the previous year.
Finally, its free cash flow grew by 26.3% to $-6M since the same quarter in the previous year.
Based on the above factors, Avicanna Inc gets an overall score of 3/5.